What are Rhythm Pharmaceuticals, Inc.'s total assets?

Rhythm Pharmaceuticals, Inc. (RYTM) holds $442.3M in total assets, up 14.4% year over year.

How much debt does Rhythm Pharmaceuticals, Inc. have?

Rhythm Pharmaceuticals, Inc. carries $112.3M in total debt against $122.9M of shareholders' equity, a debt-to-equity ratio of 0.91.

How much cash does Rhythm Pharmaceuticals, Inc. have?

Rhythm Pharmaceuticals, Inc. holds $62.1M in cash and equivalents.

Can Rhythm Pharmaceuticals, Inc. cover its short-term obligations?

Its current ratio is 4.17 — current assets exceed current liabilities.

Where does Rhythm Pharmaceuticals, Inc.'s balance sheet data come from?

Every line is extracted from Rhythm Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Rhythm Pharmaceuticals, Inc. RYTM Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$62.14M-41.4%	$54.3M-39.1%	$52.08M+9.6%	$135.59M-16.1%	$106.1M+98.6%
Short-term investments	$278.49M+33.6%	$334.65M+44.6%	$363.97M+45.1%	$155.44M-1.3%	$208.39M+41.0%
Restricted cash	$601K+29.5%	$522K+12.5%	$671K+45.2%	$527K+14.6%	$464K+0.9%
Accounts receivable, net	$119.43M+63.1%	$103.06M+47.0%	$95.49M+43.7%	$81.77M+32.5%	$73.24M+26.4%
Inventories	$95.38M+49.2%	$86.05M+61.9%	$79.04M+83.7%	$70.82M+92.0%	$63.95M+106%
Raw materials	——	——	——	——	——
Work in process	——	——	——	——	——
Finished goods	——	——	——	——	——
Prepaid expenses and other current assets	$26.62M+50.8%	$26.13M+59.5%	$23.61M+170%	$24.66M+185%	$17.66M+55.6%
Derivative assets	——	——	——	——	——
Total current assets	$430.09M+16.5%	$466.92M+24.8%	$494.8M+45.4%	$360.68M+0.9%	$369.29M+56.6%
Property and equipment, net	$1.07M+131%	$1.1M+74.7%	$237K-70.4%	$297K-69.5%	$462K-59.8%
Operating lease right-of-use assets	$2.94M-12.8%	$3.05M-12.3%	$3.16M-12.0%	$3.26M-11.7%	$3.37M+403%
Intangible assets, net	$5.11M-14.3%	$5.32M-13.8%	$5.53M-13.4%	$5.75M-12.9%	$5.96M-12.5%
Other non-current assets	$2.52M-64.8%	$3.29M-55.1%	$2.47M-79.4%	$2.22M-82.6%	$7.14M-48.2%
Total assets	$442.32M+14.4%	$480.2M+22.4%	$506.87M+39.4%	$372.73M-2.4%	$386.69M+49.5%
Accounts payable	$12.3M+3.2%	$13.95M+13.1%	$13.63M+179%	$15.98M+252%	$11.91M+57.8%
Accrued expenses	——	——	——	$40M-16.8%	$38.78M-12.9%
Deferred revenue	——	——	——	——	$1.3M-98.8%
Current portion of long-term debt	$10.13M—	$7.3M—	$5.56M—	——	——
Operating lease liabilities, current	$676K+202%	$650K—	$624K-84.5%	$510K-37.5%	$224K-71.8%
Total current liabilities	$103.2M-7.7%	$105.94M-8.3%	$104.27M+6.8%	$129.46M+137%	$111.82M+106%
Long-term debt	$98.34M—	$100.89M—	$103.41M—	——	——
Operating lease liabilities, non-current	$3.16M-17.6%	$3.34M-15.1%	$3.52M-12.8%	$3.68M+11.5%	$3.84M+1,252%
Total liabilities	$204.7M-8.5%	$210.17M-7.7%	$211.19M+0.1%	$239.15M+18.2%	$223.6M+13.5%
Preferred stock	——	——	——	——	——
Common stock	120M+193,448%	120M+196,621%	67K+9.8%	64K+6.7%	62K+3.3%
Additional paid-in capital	$1.53B+25.0%	$1.49B+26.7%	$1.45B+29.4%	$1.24B+12.0%	$1.22B+11.5%
Retained earnings	-$1.41B-16.8%	-$1.35B-17.0%	-$1.3B-17.3%	-$1.25B-17.1%	-$1.2B-16.3%
Accumulated other comprehensive income (loss)	$444K+971%	-$796K-1,941%	-$926K-53.3%	-$2.25M-264%	-$51K+71.8%
Total stockholders' equity	$122.91M+549%	$139.07M+540%	$148.82M+1,227%	-$11.91M-130%	$18.95M-69.2%
Total liabilities and stockholders' equity	$442.32M+14.4%	$480.2M+22.4%	$506.87M+39.4%	$372.73M-2.4%	$386.69M+49.5%
Available-for-Sale Debt Securities - Amortized Cost	——	——	——	——	——
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)	——	——	——	——	——
Cash, Cash Equivalents, and Marketable Securities	——	——	——	——	——
Cash Cash Equivalents And Short Term Investments	——	——	——	——	——
Raw materials and supplies inventory, gross	——	——	——	——	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	——	——
Investments - Amortized Cost Basis	——	——	——	——	——
Net Investment in Lease	$2.94M-12.8%	$3.05M-12.3%	$3.16M-12.0%	$3.26M-11.7%	$3.37M+403%
Intangible assets — net	$5.11M-14.3%	$5.32M-13.8%	$5.53M-13.4%	$5.75M-12.9%	$5.96M-12.5%
Operating lease right-of-use assets	$2.94M-12.8%	$3.05M-12.3%	$3.16M-12.0%	$3.26M-11.7%	$3.37M+403%
Strategic investments	$2.52M-64.8%	$3.29M-55.1%	$2.47M-79.4%	$2.22M-82.6%	$7.14M-48.2%
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$278.49M+33.6%	$334.65M+44.6%	$363.97M+45.1%	$155.44M-1.3%	$208.39M+41.0%
Operating Lease Right-of-Use Assets in Other Assets	$2.94M-12.8%	$3.05M-12.3%	$3.16M-12.0%	$3.26M-11.7%	$3.37M+403%
Other Investments	$2.52M-64.8%	$3.29M-55.1%	$2.47M-79.4%	$2.22M-82.6%	$7.14M-48.2%
Convertible Debt - Current	——	——	——	——	——
Deferred income	——	——	——	——	$1.3M+1.1%
Professional Service Fees Payable	——	——	——	——	——
Accrued expenses and other liabilities	$80.05M—	——	——	——	——
Total debt	$112.31M-1.1%	$112.17M-1.4%	$113.1M+2,707%	$113.98M+2,669%	$113.59M+10,447%
Common Stock Par Value Per Share	——	——	——	——	——
Common Stock Shares Issued	——	——	——	——	——
Convertible Preferred Stock Authorized Shares	——	——	——	——	——
Convertible Preferred Stock Issued Shares	——	——	——	——	——
Convertible Preferred Stock Outstanding Shares	——	——	——	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$69K+11.3%	$67K+9.8%	$67K+9.8%	$64K+6.7%	$62K+3.3%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	——	——	——	——	——
Preferred Stock Par Value Per Share	——	——	——	——	——
Temporary Equity Attributable to Parent	——	——	——	——	——
Unrealized Gains on Investments	——	——	——	——	——
Unrealized Losses on Investments (Before Tax)	——	——	——	——	——
Cumulative Cost Basis	——	——	——	——	——
Payroll related	——	——	——	——	——
Professional service fees	——	——	——	——	——
Research and development costs	——	——	——	——	——
Amount of additional consideration	——	——	——	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	——	——	——	——	——
Gross Unrealized Gains	——	——	——	——	——
Total	——	——	——	——	——
Available for sale investments	——	——	——	——	——
Cash and cash equivalents, end of period	——	——	——	——	——
Common stock, par value (in dollars per share)	——	——	——	——	——
Common stock, shares authorized (in shares)	——	——	——	——	——
Common stock, shares issued (in shares)	——	——	——	——	——
Common Stock, Shares, Outstanding	——	——	——	——	——
Fair value of embedded derivative	——	——	——	——	——
Thereafter	——	——	——	——	——
2028	——	——	——	——	——
2030	——	——	——	——	——
Remainder of 2026	——	——	——	——	——
2027	——	——	——	——	——
2029	——	——	——	——	——
Other accrued liabilities	——	——	——	——	——
Preferred Stock, Par or Stated Value Per Share	——	——	——	——	——
Preferred Stock, Shares Authorized	——	——	——	——	——
Preferred stock, authorized, including temporary equity (in shares)	——	——	——	——	——
Preferred Stock, Shares Issued	——	——	——	——	——
Preferred Stock, Shares Outstanding	——	——	——	——	——
Royalties	——	——	——	——	——
Sales allowances	——	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Rhythm Pharmaceuticals, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Rhythm Pharmaceuticals, Inc.'s total assets?: Rhythm Pharmaceuticals, Inc. (RYTM) holds $442.3M in total assets, up 14.4% year over year.
How much debt does Rhythm Pharmaceuticals, Inc. have?: Rhythm Pharmaceuticals, Inc. carries $112.3M in total debt against $122.9M of shareholders' equity, a debt-to-equity ratio of 0.91.
How much cash does Rhythm Pharmaceuticals, Inc. have?: Rhythm Pharmaceuticals, Inc. holds $62.1M in cash and equivalents.
Can Rhythm Pharmaceuticals, Inc. cover its short-term obligations?: Its current ratio is 4.17 — current assets exceed current liabilities.
Where does Rhythm Pharmaceuticals, Inc.'s balance sheet data come from?: Every line is extracted from Rhythm Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.